Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: pukrop t. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6. Lancet Haematol. 2016. PMID: 27132696 Clinical Trial.
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJM, et al. Among authors: pukrop t. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17. Lancet Haematol. 2017. PMID: 29054815 Clinical Trial.
CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma.
Herhaus P, Lipkova J, Lammer F, Yakushev I, Vag T, Slotta-Huspenina J, Habringer S, Lapa C, Pukrop T, Hellwig D, Wiestler B, Buck AK, Deckert M, Wester HJ, Bassermann F, Schwaiger M, Weber W, Menze B, Keller U. Herhaus P, et al. Among authors: pukrop t. J Nucl Med. 2020 Dec;61(12):1765-1771. doi: 10.2967/jnumed.120.241703. Epub 2020 Apr 24. J Nucl Med. 2020. PMID: 32332145 Free article.
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators. Ferreri AJM, et al. Among authors: pukrop t. Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13. Leukemia. 2022. PMID: 35562406 Clinical Trial.
Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy.
Kendziorra E, Ahlborn K, Spitzner M, Rave-Fränk M, Emons G, Gaedcke J, Kramer F, Wolff HA, Becker H, Beissbarth T, Ebner R, Ghadimi BM, Pukrop T, Ried T, Grade M. Kendziorra E, et al. Among authors: pukrop t. Carcinogenesis. 2011 Dec;32(12):1824-31. doi: 10.1093/carcin/bgr222. Epub 2011 Oct 8. Carcinogenesis. 2011. PMID: 21983179 Free PMC article.
Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism.
Menzfeld C, John M, van Rossum D, Regen T, Scheffel J, Janova H, Götz A, Ribes S, Nau R, Borisch A, Boutin P, Neumann K, Bremes V, Wienands J, Reichardt HM, Lühder F, Tischner D, Waetzig V, Herdegen T, Teismann P, Greig I, Müller M, Pukrop T, Mildner A, Kettenmann H, Brück W, Prinz M, Rotshenker S, Weber MS, Hanisch UK. Menzfeld C, et al. Among authors: pukrop t. Glia. 2015 Jun;63(6):1083-99. doi: 10.1002/glia.22803. Epub 2015 Mar 2. Glia. 2015. PMID: 25731696
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.
Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, Hüttl KS, Glehr G, Klapper W, Szczepanowski M, Richter J, Stein H, Feller AC, Möller P, Hansmann ML, Poeschel V, Held G, Loeffler M, Schmitz N, Trümper L, Pukrop T, Rosenwald A, Ott G, Spang R; Emed Demonstrator Project; German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Staiger AM, et al. Among authors: pukrop t. Leukemia. 2020 Feb;34(2):543-552. doi: 10.1038/s41375-019-0573-y. Epub 2019 Sep 17. Leukemia. 2020. PMID: 31530861 Clinical Trial.
115 results